- Home
- LITB vs BLRX Comparison
LITB vs BLRX Comparison
Compare LITB & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LITB
- BLRX
- Stock Information
- Founded
- LITB 2007
- BLRX 2003
- Country
- LITB Singapore
- BLRX Israel
- Employees
- LITB N/A
- BLRX N/A
- Industry
- LITB Catalog/Specialty Distribution
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- LITB Consumer Discretionary
- BLRX Health Care
- Exchange
- LITB Nasdaq
- BLRX Nasdaq
- Market Cap
- LITB 37.9M
- BLRX 36.0M
- IPO Year
- LITB N/A
- BLRX 2011
- Fundamental
- Price
- LITB $2.00
- BLRX $0.32
- Analyst Decision
- LITB
- BLRX Strong Buy
- Analyst Count
- LITB 0
- BLRX 2
- Target Price
- LITB N/A
- BLRX $11.50
- AVG Volume (30 Days)
- LITB 11.5K
- BLRX 880.1K
- Earning Date
- LITB 11-29-2024
- BLRX 11-25-2024
- Dividend Yield
- LITB N/A
- BLRX N/A
- EPS Growth
- LITB N/A
- BLRX N/A
- EPS
- LITB N/A
- BLRX N/A
- Revenue
- LITB $430,411,000.00
- BLRX $17,048,000.00
- Revenue This Year
- LITB N/A
- BLRX N/A
- Revenue Next Year
- LITB N/A
- BLRX N/A
- P/E Ratio
- LITB N/A
- BLRX N/A
- Revenue Growth
- LITB N/A
- BLRX N/A
- 52 Week Low
- LITB $1.77
- BLRX $0.32
- 52 Week High
- LITB $7.98
- BLRX $1.89
- Technical
- Relative Strength Index (RSI)
- LITB 40.10
- BLRX 34.04
- Support Level
- LITB $1.77
- BLRX $0.44
- Resistance Level
- LITB $2.05
- BLRX $0.56
- Average True Range (ATR)
- LITB 0.18
- BLRX 0.04
- MACD
- LITB 0.01
- BLRX 0.00
- Stochastic Oscillator
- LITB 47.92
- BLRX 1.46
About LITB LightInTheBox Holding Co. Ltd.
LightInTheBox Holding Co Ltd is an online retail company delivering products directly to consumers across the world. It provides apparel products including customized, special occasion and fast fashion apparel products; and other general merchandise products, such as accessories and gadgets, home and garden products, electronics and communication devices, and other products. The company is engaged in product sales which consisted of online retailing of consumer products. It also provides services which consisted of the provision of logistic services to e-commerce retailers and small businesses. Geographically, it operates in Europe which is the key revenue driver, North America, and other countries.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.